T-DM1, a HER2-targeted antibody-drug conjugate, improved outcomes for patients with HER2-positive, metastatic breast cancer that had progressed despite prior...
Breast-conserving surgery may be a better option than mastectomy for patients with early-stage breast cancer.
Adding denosumab (Xgeva) to adjuvant aromatase inhibitor therapy improved disease-free survival for postmenopausal women with early-stage hormone receptor-positive breast...
Studies presented at this year’s San Antonio Breast Cancer Symposium shed light on new investigational therapies for patients with...
Guest Post by Kent Osborne, MD Director of the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine;...